Vertex ‌Pharmaceuticals will buy ​Crinetics ​Pharmaceuticals for a total ⁠equity ​value of ​about $10 billion, the companies said ​on ​Monday.

These are the stocks posting the largest moves in early trading.

Here are some of the companies making headlines in midday trading.

Crinetics Pharmaceuticals won FDA approval for a drug to treat acromegaly, a rare and debilitating hormonal disorder.

In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more.

Crinetics (Nasdaq: CRNX) will showcase six presentations at ENDO 2026, June 13–16 in Chicago, highlighting its endocrine portfolio.Data span long-term PALSONIFY™ (paltusotine) safety and efficacy in acromegaly and multiple atumelnant studies in congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, plus real-world and dose-selection analyses.

Ademi LLP is probing Crinetics Pharmaceuticals to ensure public shareholders get a fair deal in its deal with Vertex, amid governance concerns.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced it will present eight abstracts from its clinical development programs at ENDO 2025, taking place July 12-15, 2025, in San Francisco. The presentations will showcase data from multiple drug candidates across their endocrinology pipeline.Key highlights include long-term efficacy and safety data for PALSONIFY™ (paltusotine) in acromegaly, featuring four abstracts demonstrating consistent biochemical and symptom control in patients. The company will present Phase 2 trial results for atumelnant in congenital adrenal hyperplasia (CAH) through three abstracts, including data on adrenal volume reduction and androgens reduction.Additionally, Crinetics will present new data from its early-stage pipeline, including CRN12755 for Graves' hyperthyroidism and orbitopathy. The company will also host two sponsored science and innovation theaters focusing on acromegaly management.

Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity ​value of about $10 billion, the companies ‌said on Monday.

Congenital Hyperinsulinism Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Rezolute, Hanmi Pharma, Zealand Pharma, Crinetics Pharma

Gilbert Cisneros filed a House STOCK Act disclosure reporting a sale of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) [ST]. Amount: $15,001. Transaction date: 2026-07-30. Filed: 2026-09-04.

Vertex Pharmaceuticalsは、稀少内分泌疾患治療薬を保有するCrinetics Pharmaceuticalsを100億ドルで買収することを発表。同取引により、Vertex is expanding its portfolio in rare genetic and metabolic disorders.

Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to its portfolio.

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all‑cash transaction that values the endocrine specialist at about $10 dollars. Under the terms of the definitive agreement...

MultiSearch Tag Explorer - Explore tags and search results by aéPiot - aéPiot: Independent SEMANTIC Web 4.0 Infrastructure (Est. 2009). High-density Functional Semantic Connectivity with 100/100 Trust...

This survey is being conducted by The Evidence Base, on behalf of Advi and Crinetics Pharmaceuticals. The findings will be shared in a forthcoming report, offering valuable insights for patients and p...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition